56. Behcet disease Clinical trials / Disease details
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01532570 (ClinicalTrials.gov) | January 2012 | 6/2/2012 | Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions | To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650 | Behcet's Disease;Behcet Syndrome;Neuro-Behcet's Disease | Drug: TA-650 | Mitsubishi Tanabe Pharma Corporation | NULL | Completed | 16 Years | 75 Years | All | 18 | Phase 3 | Japan |